MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors

Inclusion Criteria: * Able and willing to give written informed consent and had signed the appropriate written informed consent form (ICF), prior to performance of any trial activities * Eligible male and female participants aged greater than or equal to (\>=)20 years * Histologically or cytologically proven metastatic or locally advanced solid tumors, for which no effective standard therapy exists or standard therapy had failed * Eastern Cooperative Oncology Group performance status (ECOG) performance status of 0 to 1 at trial entry * Life expectancy \>=12 weeks as judged by the Investigator. * Adequate hematological function defined by white blood cell (WBC) count \>=3\*10\^9/Liter with absolute neutrophil count (ANC) \>=1.5\*10\^9/Liter, lymphocyte count \>=0.5\* 10\^9/Liter, platelet count \>=75\*10\^9/Liter, and Hemoglobin (Hgb) \>= 9 grams per deciliter (g/dL) (in absence of blood transfusion) * Adequate hepatic function defined by a total bilirubin level \<=1.5 × Upper limit of normal (ULN), an AST level \<= 2.5 × ULN, and an ALT level \<= 2.5 × ULN * Adequate renal function defined by an estimated creatinine clearance \>50 milliliter per minute (mL/min) according to the Cockcroft-Gault formula or by measure of creatinine clearance from 24 hour urine collection Other protocol-defined exclusion criteria could apply. Exclusion Criteria: * Concurrent treatment with non-permitted drugs and other interventions * Anticancer treatment within 28 days before the start of tr…